Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025.
Revenue is expected to grow to between $515 million and $517 million, an increase of approximately 16%.
Key metrics include testing revenue growth of 17-18% and testing volume increase of 19%.
Revenue Growth
Total revenue is expected to increase by 16% compared to the previous year.
Testing Volume
Testing volume is projected to grow by 19% in 2025.
Future Outlook
Veracyte anticipates a total revenue growth of 10-13% in 2026, with further expansion in testing revenue.
- Veracyte expects adjusted EBITDA margin of greater than 25% for the full year 2025, showing strong financial performance and profitability.
- The company's innovative tests, including Decipher and Afirma, have significantly impacted patients, with a continuous growth trajectory expected in 2026.
Veracyte's robust financial results and positive outlook for 2026 demonstrate their commitment to transforming cancer care and driving continued growth.